Currently, both drugs have been approved by the FDA for the treatment of patients more than 12 years of age with advanced or metastatic RET-mutant MTC, RET fusion-positive metastatic NSCLC, and advanced or metastatic RET fusion-positive thyroid cancer patients who require systemic therapy and who are radioactive iodine refractory. The gene discussed is RET; the disease is thyroid gland carcinoma.